A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Clinical trial NCT01826448 · TERMINATED

Trial details

NCT number: NCT01826448
Sponsor: Daiichi Sankyo
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

V600-mutated BRAF Unresectable Melanoma V600-mutated BRAF Metastatic Melanoma Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor

Start date: 2013-11-05
Primary completion: 2014-09-22
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.